We also demonstrated that podocalyxin overexpression serves as an independent prognostic factor for poor progression-free survival among NAT patients only if the response to NAT was insubstantial, such that more than 50% of the viable residual tumor cells could be seen post-pancreatectomy. Here, PODXL is linked to neoplasm.